A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.
Phase 1
- Conditions
- Chronic HCV Hepatitis C
- Registration Number
- NCT01164384
- Lead Sponsor
- University of Zurich
- Brief Summary
Erstes Safety Trial mit Baminercept in chronischen HCV Patienten. Untersuchung des potentiell antiviralen, antiinflammatorischen Effekts sowie Modulation der hepatischen Gen-Expression.
10 Patienten, open label, 10 Wochen Therapie. Sequentielles Enrollement der ersten 4 Patienten.
* Trial with medicinal product
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Sicherheit
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Baminercept's antiviral and anti-inflammatory effects in chronic HCV hepatitis?
How does Baminercept's safety profile compare to standard-of-care interferon-based therapies for HCV in Phase 1 trials?
Which hepatic biomarkers correlate with response to CD27 antagonism in NCT01164384 HCV patients?
What adverse events were observed in the open-label Baminercept Phase 1b trial for chronic HCV, and how were they managed?
Are there combination therapies involving Baminercept and direct-acting antivirals (DAAs) being explored for HCV treatment post-2013?